摘要 |
<p>The present invention relates to solid amorphous form of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (compound 1), pharmaceutical compositions thereof, solid dispersions thereof and the compound 1 for use in the treatment of a CFRT mediated diseases such as cytosic fibrosis</p> |